DOCSLIB.ORG

Thedacare Disease Management Program Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Thedacare Disease Management Program Drug List ThedaCare Disease Management Program Drug List BRAND_NAME GENERIC_NAME ACARBOSE ACARBOSE ACARBOSE ACARBOSE ACARBOSE ACARBOSE ACCUPRIL QUINAPRIL HCL ACCUPRIL QUINAPRIL HCL ADMELOG INSULIN LISPRO ADMELOG SOLOSTAR INSULIN LISPRO ALDACTAZIDE SPIRONOLACT/HYDROCHLOROTHIAZID AMILORIDE HCL AMILORIDE HCL AMILORIDE-HYDROCHLOROTHIAZIDE AMILORIDE/HYDROCHLOROTHIAZIDE AMLODIPINE BESYLATE AMLODIPINE BESYLATE AMLODIPINE BESYLATE AMLODIPINE BESYLATE AMLODIPINE BESYLATE AMLODIPINE BESYLATE AMLODIPINE BESYLATE-BENAZEPRIL AMLODIPINE BESYLATE/BENAZEPRIL AMLODIPINE BESYLATE-BENAZEPRIL AMLODIPINE BESYLATE/BENAZEPRIL AMLODIPINE BESYLATE-BENAZEPRIL AMLODIPINE BESYLATE/BENAZEPRIL AMLODIPINE-VALSARTAN AMLODIPINE BESYLATE/VALSARTAN AMLODIPINE-VALSARTAN AMLODIPINE BESYLATE/VALSARTAN AMLODIPINE-VALSARTAN AMLODIPINE BESYLATE/VALSARTAN AMLODIPINE-VALSARTAN AMLODIPINE BESYLATE/VALSARTAN ASPIRIN-DIPYRIDAMOLE ER ASPIRIN/DIPYRIDAMOLE ATENOLOL ATENOLOL ATENOLOL ATENOLOL ATENOLOL ATENOLOL ATORVASTATIN CALCIUM ATORVASTATIN CALCIUM ATORVASTATIN CALCIUM ATORVASTATIN CALCIUM ATORVASTATIN CALCIUM ATORVASTATIN CALCIUM ATORVASTATIN CALCIUM ATORVASTATIN CALCIUM BENAZEPRIL HCL BENAZEPRIL HCL BENAZEPRIL HCL BENAZEPRIL HCL BENAZEPRIL HCL BENAZEPRIL HCL BENAZEPRIL HCL BENAZEPRIL HCL BENAZEPRIL-HYDROCHLOROTHIAZIDE BENAZEPRIL/HYDROCHLOROTHIAZIDE BENAZEPRIL-HYDROCHLOROTHIAZIDE BENAZEPRIL/HYDROCHLOROTHIAZIDE BENAZEPRIL-HYDROCHLOROTHIAZIDE BENAZEPRIL/HYDROCHLOROTHIAZIDE BENAZEPRIL-HYDROCHLOROTHIAZIDE BENAZEPRIL/HYDROCHLOROTHIAZIDE BISOPROLOL FUMARATE BISOPROLOL FUMARATE BISOPROLOL FUMARATE BISOPROLOL FUMARATE BISOPROLOL-HYDROCHLOROTHIAZIDE BISOPROLOL/HYDROCHLOROTHIAZIDE BISOPROLOL-HYDROCHLOROTHIAZIDE BISOPROLOL/HYDROCHLOROTHIAZIDE BISOPROLOL-HYDROCHLOROTHIAZIDE BISOPROLOL/HYDROCHLOROTHIAZIDE BRILINTA TICAGRELOR BRAND_NAME GENERIC_NAME BUMETANIDE BUMETANIDE BUMETANIDE BUMETANIDE BUMETANIDE BUMETANIDE BYDUREON EXENATIDE MICROSPHERES BYDUREON BCISE EXENATIDE MICROSPHERES BYDUREON BCISE EXENATIDE MICROSPHERES BYDUREON PEN EXENATIDE MICROSPHERES BYETTA EXENATIDE BYETTA EXENATIDE CAPTOPRIL CAPTOPRIL CAPTOPRIL CAPTOPRIL CAPTOPRIL CAPTOPRIL CAPTOPRIL CAPTOPRIL CAPTOPRIL-HYDROCHLOROTHIAZIDE CAPTOPRIL/HYDROCHLOROTHIAZIDE CAPTOPRIL-HYDROCHLOROTHIAZIDE CAPTOPRIL/HYDROCHLOROTHIAZIDE CAPTOPRIL-HYDROCHLOROTHIAZIDE CAPTOPRIL/HYDROCHLOROTHIAZIDE CAPTOPRIL-HYDROCHLOROTHIAZIDE CAPTOPRIL/HYDROCHLOROTHIAZIDE CARVEDILOL CARVEDILOL CARVEDILOL CARVEDILOL CARVEDILOL CARVEDILOL CARVEDILOL CARVEDILOL CHLOROTHIAZIDE CHLOROTHIAZIDE CHLOROTHIAZIDE CHLOROTHIAZIDE CHLORTHALIDONE CHLORTHALIDONE CHLORTHALIDONE CHLORTHALIDONE CHOLESTYRAMINE CHOLESTYRAMINE (WITH SUGAR) CHOLESTYRAMINE LIGHT CHOLESTYRAMINE/ASPARTAME CHOLESTYRAMINE LIGHT CHOLESTYRAMINE/ASPARTAME CILOSTAZOL CILOSTAZOL CILOSTAZOL CILOSTAZOL CLONIDINE CLONIDINE CLONIDINE CLONIDINE CLONIDINE CLONIDINE CLONIDINE HCL CLONIDINE HCL CLONIDINE HCL CLONIDINE HCL CLONIDINE HCL CLONIDINE HCL CLOPIDOGREL CLOPIDOGREL BISULFATE COLESTIPOL HCL COLESTIPOL HCL CYCLOSET BROMOCRIPTINE MESYLATE DILTIAZEM 12HR ER DILTIAZEM HCL DILTIAZEM 12HR ER DILTIAZEM HCL DILTIAZEM 12HR ER DILTIAZEM HCL DILTIAZEM 24HR ER DILTIAZEM HCL DILTIAZEM 24HR ER DILTIAZEM HCL DILTIAZEM 24HR ER DILTIAZEM HCL DILTIAZEM 24HR ER DILTIAZEM HCL DILTIAZEM 24HR ER DILTIAZEM HCL DILTIAZEM 24HR ER DILTIAZEM HCL DILTIAZEM 24HR ER (CD) DILTIAZEM HCL DILTIAZEM 24HR ER (CD) DILTIAZEM HCL DILTIAZEM 24HR ER (CD) DILTIAZEM HCL DILTIAZEM 24HR ER (CD) DILTIAZEM HCL DILTIAZEM 24HR ER (CD) DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL BRAND_NAME GENERIC_NAME DILT-XR DILTIAZEM HCL DILT-XR DILTIAZEM HCL DILT-XR DILTIAZEM HCL DIPYRIDAMOLE DIPYRIDAMOLE DIPYRIDAMOLE DIPYRIDAMOLE DIPYRIDAMOLE DIPYRIDAMOLE DIURIL CHLOROTHIAZIDE DOXAZOSIN MESYLATE DOXAZOSIN MESYLATE DOXAZOSIN MESYLATE DOXAZOSIN MESYLATE DOXAZOSIN MESYLATE DOXAZOSIN MESYLATE DOXAZOSIN MESYLATE DOXAZOSIN MESYLATE DUETACT PIOGLITAZONE HCL/GLIMEPIRIDE DUETACT PIOGLITAZONE HCL/GLIMEPIRIDE ENALAPRIL MALEATE ENALAPRIL MALEATE ENALAPRIL MALEATE ENALAPRIL MALEATE ENALAPRIL-HYDROCHLOROTHIAZIDE ENALAPRIL/HYDROCHLOROTHIAZIDE ENALAPRIL-HYDROCHLOROTHIAZIDE ENALAPRIL/HYDROCHLOROTHIAZIDE EPLERENONE EPLERENONE EPLERENONE EPLERENONE ETHACRYNIC ACID ETHACRYNIC ACID EXFORGE HCT AMLODIPINE/VALSARTAN/HCTHIAZID EXFORGE HCT AMLODIPINE/VALSARTAN/HCTHIAZID EXFORGE HCT AMLODIPINE/VALSARTAN/HCTHIAZID EXFORGE HCT AMLODIPINE/VALSARTAN/HCTHIAZID EXFORGE HCT AMLODIPINE/VALSARTAN/HCTHIAZID EZETIMIBE EZETIMIBE FENOFIBRATE FENOFIBRATE,MICRONIZED FENOFIBRATE FENOFIBRATE NANOCRYSTALLIZED FENOFIBRATE FENOFIBRATE FENOFIBRATE FENOFIBRATE,MICRONIZED FENOFIBRATE FENOFIBRATE FENOFIBRATE FENOFIBRATE,MICRONIZED FENOFIBRATE FENOFIBRATE NANOCRYSTALLIZED FOSINOPRIL SODIUM FOSINOPRIL SODIUM FOSINOPRIL SODIUM FOSINOPRIL SODIUM FOSINOPRIL SODIUM FOSINOPRIL SODIUM FOSINOPRIL-HYDROCHLOROTHIAZIDE FOSINOPRIL/HYDROCHLOROTHIAZIDE FOSINOPRIL-HYDROCHLOROTHIAZIDE FOSINOPRIL/HYDROCHLOROTHIAZIDE FUROSEMIDE FUROSEMIDE FUROSEMIDE FUROSEMIDE FUROSEMIDE FUROSEMIDE FUROSEMIDE FUROSEMIDE FUROSEMIDE FUROSEMIDE GEMFIBROZIL GEMFIBROZIL GLIMEPIRIDE GLIMEPIRIDE GLIMEPIRIDE GLIMEPIRIDE GLIMEPIRIDE GLIMEPIRIDE GLIPIZIDE GLIPIZIDE GLIPIZIDE GLIPIZIDE GLIPIZIDE ER GLIPIZIDE GLIPIZIDE ER GLIPIZIDE GLIPIZIDE ER GLIPIZIDE GLIPIZIDE-METFORMIN GLIPIZIDE/METFORMIN HCL GLIPIZIDE-METFORMIN GLIPIZIDE/METFORMIN HCL GLIPIZIDE-METFORMIN GLIPIZIDE/METFORMIN HCL GLUCAGEN GLUCAGON,HUMAN RECOMBINANT GLUCAGON EMERGENCY KIT GLUCAGON,HUMAN RECOMBINANT GLYSET MIGLITOL BRAND_NAME GENERIC_NAME GLYSET MIGLITOL GUANFACINE HCL GUANFACINE HCL GUANFACINE HCL GUANFACINE HCL HUMALOG INSULIN LISPRO HUMALOG JUNIOR KWIKPEN INSULIN LISPRO HUMALOG KWIKPEN U-200 INSULIN LISPRO HUMALOG MIX 50-50 INSULIN LISPRO PROTAMIN/LISPRO HUMALOG MIX 50-50 KWIKPEN INSULIN LISPRO PROTAMIN/LISPRO HUMALOG MIX 75-25 INSULIN LISPRO PROTAMIN/LISPRO HUMALOG MIX 75-25 KWIKPEN INSULIN LISPRO PROTAMIN/LISPRO HUMULIN R INSULIN REGULAR, HUMAN HUMULIN R INSULIN REGULAR, HUMAN HUMULIN R INSULIN REGULAR, HUMAN HUMULIN R U-500 INSULIN REGULAR, HUMAN HUMULIN R U-500 KWIKPEN INSULIN REGULAR, HUMAN HYDRALAZINE HCL HYDRALAZINE HCL HYDRALAZINE HCL HYDRALAZINE HCL HYDRALAZINE HCL HYDRALAZINE HCL HYDRALAZINE HCL HYDRALAZINE HCL HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE INDAPAMIDE INDAPAMIDE INDAPAMIDE INDAPAMIDE INDERAL LA PROPRANOLOL HCL INDERAL LA PROPRANOLOL HCL INDERAL LA PROPRANOLOL HCL INDERAL LA PROPRANOLOL HCL INSULIN LISPRO INSULIN LISPRO INSULIN LISPRO KWIKPEN U-100 INSULIN LISPRO INSULIN LISPRO KWIKPEN U-100 INSULIN LISPRO INVOKAMET CANAGLIFLOZIN/METFORMIN HCL INVOKAMET CANAGLIFLOZIN/METFORMIN HCL INVOKAMET CANAGLIFLOZIN/METFORMIN HCL INVOKAMET CANAGLIFLOZIN/METFORMIN HCL INVOKAMET XR CANAGLIFLOZIN/METFORMIN HCL INVOKAMET XR CANAGLIFLOZIN/METFORMIN HCL INVOKAMET XR CANAGLIFLOZIN/METFORMIN HCL INVOKAMET XR CANAGLIFLOZIN/METFORMIN HCL INVOKANA CANAGLIFLOZIN INVOKANA CANAGLIFLOZIN IRBESARTAN IRBESARTAN IRBESARTAN IRBESARTAN IRBESARTAN IRBESARTAN IRBESARTAN-HYDROCHLOROTHIAZIDE IRBESARTAN/HYDROCHLOROTHIAZIDE IRBESARTAN-HYDROCHLOROTHIAZIDE IRBESARTAN/HYDROCHLOROTHIAZIDE ISORDIL ISOSORBIDE DINITRATE ISOSORBIDE DINITRATE ISOSORBIDE DINITRATE ISOSORBIDE DINITRATE ISOSORBIDE DINITRATE ISOSORBIDE DINITRATE ISOSORBIDE DINITRATE ISOSORBIDE DINITRATE ISOSORBIDE DINITRATE ISOSORBIDE DINITRATE ER ISOSORBIDE DINITRATE BRAND_NAME GENERIC_NAME ISOSORBIDE MONONITRATE ISOSORBIDE MONONITRATE ISOSORBIDE MONONITRATE ISOSORBIDE MONONITRATE ISOSORBIDE MONONITRATE ER ISOSORBIDE MONONITRATE ISOSORBIDE MONONITRATE ER ISOSORBIDE MONONITRATE ISOSORBIDE MONONITRATE ER ISOSORBIDE MONONITRATE JARDIANCE EMPAGLIFLOZIN JARDIANCE EMPAGLIFLOZIN JENTADUETO LINAGLIPTIN/METFORMIN HCL JENTADUETO LINAGLIPTIN/METFORMIN HCL JENTADUETO LINAGLIPTIN/METFORMIN HCL JENTADUETO XR LINAGLIPTIN/METFORMIN HCL JENTADUETO XR LINAGLIPTIN/METFORMIN HCL LABETALOL HCL LABETALOL HCL LABETALOL HCL LABETALOL HCL LABETALOL HCL LABETALOL HCL LANTUS INSULIN GLARGINE,HUM.REC.ANLOG LANTUS INSULIN GLARGINE,HUM.REC.ANLOG LANTUS SOLOSTAR INSULIN GLARGINE,HUM.REC.ANLOG LANTUS SOLOSTAR INSULIN GLARGINE,HUM.REC.ANLOG LANTUS SOLOSTAR INSULIN GLARGINE,HUM.REC.ANLOG LANTUS SOLOSTAR INSULIN GLARGINE,HUM.REC.ANLOG LANTUS SOLOSTAR INSULIN GLARGINE,HUM.REC.ANLOG LANTUS SOLOSTAR INSULIN GLARGINE,HUM.REC.ANLOG LEVALBUTEROL TARTRATE HFA LEVALBUTEROL TARTRATE LEVALBUTEROL TARTRATE HFA LEVALBUTEROL TARTRATE LEVEMIR INSULIN DETEMIR LEVEMIR FLEXTOUCH INSULIN DETEMIR LIPTRUZET EZETIMIBE/ATORVASTATIN CALCIUM LIPTRUZET EZETIMIBE/ATORVASTATIN CALCIUM LIPTRUZET EZETIMIBE/ATORVASTATIN CALCIUM LIPTRUZET EZETIMIBE/ATORVASTATIN CALCIUM LISINOPRIL LISINOPRIL LISINOPRIL LISINOPRIL LISINOPRIL LISINOPRIL LISINOPRIL LISINOPRIL LISINOPRIL LISINOPRIL LISINOPRIL LISINOPRIL LISINOPRIL-HYDROCHLOROTHIAZIDE LISINOPRIL/HYDROCHLOROTHIAZIDE LISINOPRIL-HYDROCHLOROTHIAZIDE LISINOPRIL/HYDROCHLOROTHIAZIDE LISINOPRIL-HYDROCHLOROTHIAZIDE LISINOPRIL/HYDROCHLOROTHIAZIDE LOSARTAN POTASSIUM LOSARTAN POTASSIUM LOSARTAN POTASSIUM LOSARTAN POTASSIUM LOSARTAN POTASSIUM LOSARTAN POTASSIUM LOSARTAN-HYDROCHLOROTHIAZIDE LOSARTAN/HYDROCHLOROTHIAZIDE LOSARTAN-HYDROCHLOROTHIAZIDE LOSARTAN/HYDROCHLOROTHIAZIDE LOSARTAN-HYDROCHLOROTHIAZIDE LOSARTAN/HYDROCHLOROTHIAZIDE LOTREL AMLODIPINE BESYLATE/BENAZEPRIL LOTREL AMLODIPINE BESYLATE/BENAZEPRIL LOTREL AMLODIPINE BESYLATE/BENAZEPRIL LOVASTATIN LOVASTATIN LOVASTATIN LOVASTATIN LOVASTATIN LOVASTATIN METFORMIN HCL METFORMIN HCL BRAND_NAME GENERIC_NAME METFORMIN HCL METFORMIN HCL METFORMIN
Load more

Recommended publications
  • Table 2. 2012 AGS Beers Criteria for Potentially
    Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May
    [Show full text]
  • Topically Applied Minoxidil in Baldness
    Review Topically Applied Minoxidil in Baldness ERVIN NOVAK,M.D., THOMASJ. FRANZ, M.D., JOHN T. HEADINGTON,M.D., AND RONALD C. WESTER,PH.D. From the Upjohn Company, Kalamazoo, Michigan, School idil and its metabolites can be removed by hemodi- of Medicine, University of Washington, Seattle, alysis. Washington, Medical School, University of Michigan, Ann Fluid retention and hypertrichosis are the most Arbor, Michigan, and School of Medicine and School of Pharmacy, University of California, San Francisco, California commonly occurring side effects of minoxidil. Hair regrowth in a patient with male pattern baldness was described in a case report of a hypertensive patient treated twice daily with 20 mg oral minoxidil.6 The Minoxidil, an orally administered, peripheral va- extensive hair regrowth continued after 10 months sodilator used to treat hypertension, causes hypertri- of therapy. New and increased hair growth as a side chosis in more than 80% of users. The drug reduces effect was also detected in an early clinical study elevated blood pressure by decreasing peripheral involving five of eight patients on oral minoxidil vascular resistance. Chemically, minoxidil is 2,4-di- therapy for 2 month^.^ Zappacosta' reported reversal amino-6-piperidinopyrimidine-3-oxide; it is soluble in of baldness in a patient on minoxidil for the treatment water to the extent of approximately 2 mg/ml, is of hypertension. more readily soluble in propylene glycol or ethanol, After the third week of therapy with oral minoxidil, and is nearly insoluble in acetone, chloroform, or hypertrichosis usually appears between the eyebrows ethyl acetate. Following oral administration of minox- and the hair line, in the malar and temporal areas, idil and in association with the reduction in peripheral on the backs of the arms, on the shoulders, and on vascular resistance, cardiac output is augmented, salt the legs.
    [Show full text]
  • ALLHAT Protocol, Can Enter the Trial at the Discretion of the Principal Investigator Or His/Her Designee
    Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Protocol Revised: March 1995 May 1995 April 1998 April 2000 April 2000 Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Protocol Table of Contents Page I. Overview............................................................................................................................ 2 II. Background........................................................................................................................ 4 III. Hypotheses and Study Power ........................................................................................... 10 IV. Eligibility and Exclusions................................................................................................. 13 V. Recruitment....................................................................................................................... 17 VI. Antihypertensive Intervention .......................................................................................... 22 VII. Cholesterol-Lowering Intervention................................................................................... 26 VIII. Laboratory Measurements ................................................................................................ 28 IX. Outcome Measurements.................................................................................................... 30 X. Study Organization ..........................................................................................................
    [Show full text]
  • Ace Inhibitors (Angiotensin-Converting Enzyme)
    Medication Instructions Ace Inhibitors (Angiotensin-Converting Enzyme) Generic Brand Benazepril Lotensin Captopril Capoten Enalapril Vasotec Fosinopril Monopril Lisinopril Prinivil, Zestril Do not Moexipril Univasc Quinapril Accupril stop taking Ramipril Altace this medicine Trandolapril Mavik About this Medicine unless told ACE inhibitors are used to treat both high blood pressure (hypertension) and heart failure (HF). They block an enzyme that causes blood vessels to constrict. This to do so allows the blood vessels to relax and dilate. Untreated, high blood pressure can damage to your heart, kidneys and may lead to stroke or heart failure. In HF, using by your an ACE inhibitor can: • Protect your heart from further injury doctor. • Improve your health • Reduce your symptoms • Can prevent heart failure. Generic forms of ACE Inhibitors (benazepril, captopril, enalapril, fosinopril, and lisinopril) may be purchased at a lower price. There are no “generics” for Accupril, Altace Mavik, and of Univasc. Thus their prices are higher. Ask your doctor if one of the generic ACE Inhibitors would work for you. How to Take Use this drug as directed by your doctor. It is best to take these drugs, especially captopril, on an empty stomach one hour before or two hours after meals (unless otherwise instructed by your doctor). Side Effects Along with needed effects, a drug may cause some unwanted effects. Many people will not have any side effects. Most of these side effects are mild and short-lived. Check with your doctor if any of the following side effects occur: • Fever and chills • Hoarseness • Swelling of face, mouth, hands or feet or any trouble in swallowing or breathing • Dizziness or lightheadedness (often a problem with the first dose) Report these side effects if they persist: • Cough – dry or continuing • Loss of taste, diarrhea, nausea, headache or unusual fatigue • Fast or irregular heartbeat, dizziness, lightheadedness • Skin rash Special Guidelines • Sodium in the diet may cause you to retain fluid and increase your blood pressure.
    [Show full text]
  • "Coaprovel, INN-Irbesartan+Hydrochlorothiazide"
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT CoAprovel 150 mg/12.5 mg tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide. Excipient with known effect: Each tablet contains 26.65 mg of lactose (as lactose monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. Peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2775 engraved on the other side. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (see section 5.1). 4.2 Posology and method of administration Posology CoAprovel can be taken once daily, with or without food. Dose titration with the individual components (i.e. irbesartan and hydrochlorothiazide) may be recommended. When clinically appropriate direct change from monotherapy to the fixed combinations may be considered: . CoAprovel 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone; . CoAprovel 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by CoAprovel 150 mg/12.5 mg. CoAprovel 300 mg/25 mg may be administered in patients insufficiently controlled by CoAprovel 300 mg/12.5 mg. Doses higher than 300 mg irbesartan/25 mg hydrochlorothiazide once daily are not recommended. When necessary, CoAprovel may be administered with another antihypertensive medicinal product (see sections 4.3, 4.4, 4.5 and 5.1).
    [Show full text]
  • Benign Prostatic Hyperplasia (BPH) Treatments Review 10/05/2009
    Benign Prostatic Hyperplasia (BPH) Treatments Review 10/05/2009 Copyright © 2004 - 2009 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein,
    [Show full text]
  • Antiparasitic Properties of Cardiovascular Agents Against Human Intravascular Parasite Schistosoma Mansoni
    pharmaceuticals Article Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite Schistosoma mansoni Raquel Porto 1, Ana C. Mengarda 1, Rayssa A. Cajas 1, Maria C. Salvadori 2 , Fernanda S. Teixeira 2 , Daniel D. R. Arcanjo 3 , Abolghasem Siyadatpanah 4, Maria de Lourdes Pereira 5 , Polrat Wilairatana 6,* and Josué de Moraes 1,* 1 Research Center for Neglected Diseases, Guarulhos University, Praça Tereza Cristina 229, São Paulo 07023-070, SP, Brazil; [email protected] (R.P.); [email protected] (A.C.M.); [email protected] (R.A.C.) 2 Institute of Physics, University of São Paulo, São Paulo 05508-060, SP, Brazil; [email protected] (M.C.S.); [email protected] (F.S.T.) 3 Department of Biophysics and Physiology, Federal University of Piaui, Teresina 64049-550, PI, Brazil; [email protected] 4 Ferdows School of Paramedical and Health, Birjand University of Medical Sciences, Birjand 9717853577, Iran; [email protected] 5 CICECO-Aveiro Institute of Materials & Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal; [email protected] 6 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand * Correspondence: [email protected] (P.W.); [email protected] (J.d.M.) Citation: Porto, R.; Mengarda, A.C.; Abstract: The intravascular parasitic worm Schistosoma mansoni is a causative agent of schistosomiasis, Cajas, R.A.; Salvadori, M.C.; Teixeira, a disease of great global public health significance. Praziquantel is the only drug available to F.S.; Arcanjo, D.D.R.; Siyadatpanah, treat schistosomiasis and there is an urgent demand for new anthelmintic agents.
    [Show full text]
  • Tetracaine and Oxymetazoline
    PATIENT & CAREGIVER EDUCATION Tetracaine and Oxymetazoline This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. What is this drug used for? It is used before dental care to numb the area. What do I need to tell the doctor BEFORE my child takes this drug? If your child is allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell the doctor about the allergy and what signs your child had. If your child has thyroid disease, talk with the doctor. If your child has high blood pressure. If your child has methemoglobinemia. If your child is taking certain drugs used for depression like isocarboxazid, phenelzine, or tranylcypromine, or drugs used for certain other health problems like selegiline or rasagiline. If your child is taking or has recently taken any drugs for mental or mood problems like depression. There are many drugs that Tetracaine and Oxymetazoline 1/7 must not be taken with this drug. Talk with your child’s doctor if you are not sure. If your child is taking any of these drugs: Nadolol, penbutolol, pindolol, propranolol, sotalol, or timolol. If your child has used another drug in the last 24 hours that has the same drug in it. If your child is using another drug in the nose. If your child weighs less than 88 pounds (40 kilograms). This drug is not for use in children who weigh less than 88 pounds (40 kilograms).
    [Show full text]
  • New Drug Evaluation Monograph Template
    Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 © Copyright 2012 Oregon State University. All Rights Reserved Month/Year of Review: January 2014 Date of Last Review: January 2012 PDL Classes: Beta Blockers Source Document: OSU College of Pharmacy Current Status of PDL Class: Preferred Agents: ACEBUTOLOL HCL, ATENOLOL, CARVEDILOL, LABETALOL HCL, METOPROLOL TARTRATE, NADOLOL, PROPRANOLOL HCL Non-Preferred Agents: BETAXOLOL, BISOPROLOL, METOPROLOL SUCCINATE, NEBIVOLOL (BYSTOLIC®), PENBUTOLOL (LEVABUTOL®), PINDOLOL, TIMOLOL Previous Conclusions and Recommendation: In patients with mild-moderate HF, bisoprolol, carvedilol or metoprolol succinate (ER) reduce mortality. In patients with severe HF, carvedilol or metoprolol succinate (ER) reduce mortality. In patients with recent MI, acebutolol, carvedilol, metoprolol tartrate (IR), propranolol, or timolol reduce mortality. It is important that at least one of these drugs be included in the PDL. All of the β-Blockers reviewed are effective in the treatment of hypertension, but there is no evidence of differences between β-blockers for blood pressure control, survival, or quality of life. All of the β-Blockers reviewed except carteolol reduced anginal attacks in patients in short-term studies that did not allow mortality evaluation. Because of their effectiveness in rate control for atrial fibrillation at least one of either atenolol, bisoprolol, carvedilol, metoprolol succinate (ER), nadolol, pindolol, or propranolol should be included in the PDL. The current evidence does not distinguish a difference among these beneficial β−Blockers that were tested for preventing recurrence and diminishing the severity of migraine headaches: atenolol, bisoprolol, metoprolol tartrate (IR), metoprolol succinate (ER), propranolol, propranolol LA nadolol, or timolol.
    [Show full text]
  • Label-Free Cell Phenotypic Profiling Decodes the Composition And
    OPEN Label-free cell phenotypic profiling SUBJECT AREAS: decodes the composition and signaling POTASSIUM CHANNELS SENSORS AND PROBES of an endogenous ATP-sensitive Received potassium channel 28 January 2014 Haiyan Sun1*, Ying Wei1, Huayun Deng1, Qiaojie Xiong2{, Min Li2, Joydeep Lahiri1 & Ye Fang1 Accepted 24 April 2014 1Biochemical Technologies, Science and Technology Division, Corning Incorporated, Corning, NY 14831, United States of Published America, 2The Solomon H. Snyder Department of Neuroscience and High Throughput Biology Center, Johns Hopkins University 12 May 2014 School of Medicine, Baltimore, Maryland 21205, United States of America. Current technologies for studying ion channels are fundamentally limited because of their inability to Correspondence and functionally link ion channel activity to cellular pathways. Herein, we report the use of label-free cell requests for materials phenotypic profiling to decode the composition and signaling of an endogenous ATP-sensitive potassium should be addressed to ion channel (KATP) in HepG2C3A, a hepatocellular carcinoma cell line. Label-free cell phenotypic agonist Y.F. (fangy2@corning. profiling showed that pinacidil triggered characteristically similar dynamic mass redistribution (DMR) com) signals in A431, A549, HT29 and HepG2C3A, but not in HepG2 cells. Reverse transcriptase PCR, RNAi knockdown, and KATP blocker profiling showed that the pinacidil DMR is due to the activation of SUR2/ Kir6.2 KATP channels in HepG2C3A cells. Kinase inhibition and RNAi knockdown showed that the pinacidil * Current address: activated KATP channels trigger signaling through Rho kinase and Janus kinase-3, and cause actin remodeling. The results are the first demonstration of a label-free methodology to characterize the Biodesign Institute, composition and signaling of an endogenous ATP-sensitive potassium ion channel.
    [Show full text]
  • Acquired Hypertrichosis of the Periorbital Area and Malar Cheek
    PHOTO CHALLENGE Acquired Hypertrichosis of the Periorbital Area and Malar Cheek Caitlin G. Purvis, BS; Justin P. Bandino, MD; Dirk M. Elston, MD An otherwise healthy woman in her late 50s with Fitzpatrick skin type II presented to the derma- tology department for a scheduled cosmetic botulinum toxin injection. Her medical history was notable only for periodic nonsurgical cosmetic procedures including botulinum toxin and dermal fillers, and she was not taking any daily systemic medications. Duringcopy the preoperative assess- ment, subtle bilateral and symmetric hypertricho- sis with darker terminal hair formation was noted on the periorbital skin and zygomatic cheek. Uponnot inquiry, the patient admitted to purchas- ing a “special eye drop” from Mexico and using it regularly. After instillation of 2 to 3 drops per eye, she would laterally wipe the resulting excess Dodrops away from the eyes with her hands and then wash her hands. She denied a change in eye color from their natural brown but did report using blue color contact lenses. She denied an increase in hair growth elsewhere including the upper lip, chin, upper chest, forearms, and hands. She denied deepening of her voice, CUTIS acne, or hair thinning. WHAT’S THE DIAGNOSIS? a. acetazolamide-induced hypertrichosis b. betamethasone-induced hypertrichosis c. bimatoprost-induced hypertrichosis d. cyclosporine-induced hypertrichosis e. timolol-induced hypertrichosis PLEASE TURN TO PAGE E21 FOR THE DIAGNOSIS From the Department of Dermatology, Medical University of South Carolina, Charleston. The authors report no conflict of interest. Correspondence: Justin P. Bandino, MD, 171 Ashley Ave, MSC 908, Charleston, SC 29425 ([email protected]).
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]